Patents Assigned to Los Angeles Biomedical Research Institute
-
Patent number: 10358465Abstract: The present invention relates to synthetic lung surfactant compositions that include a novel surface active peptide and a phospholipid, including phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, naturally occurring phospholipids, or a combination thereof. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue and to deliver therapeutic agents are also disclosed.Type: GrantFiled: October 20, 2017Date of Patent: July 23, 2019Assignees: Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center, University of RochesterInventors: Alan J. Waring, Frans J. Walther, Larry M. Gordon, Robert H. Notter
-
Patent number: 10329336Abstract: The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an ?-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a ?KO core and that can be a CXC, CC, or C class chemokine. Structural, physicochemical and functional properties of this novel class of antimicrobial peptides and amino acid sequences of particular kinocidin peptides are also disclosed. The invention also provides related antimicrobial methods.Type: GrantFiled: September 4, 2018Date of Patent: June 25, 2019Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Nannette Y. Yount, Michael R. Yeaman
-
Patent number: 10300120Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue.Type: GrantFiled: February 3, 2016Date of Patent: May 28, 2019Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: John E. Edwards, Jr., Ashraf S. Ibrahim, Bradley J. Spellberg, Yue Fu, Scott G. Filler, Michael R. Yeaman
-
Publication number: 20190151301Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: ApplicationFiled: November 21, 2018Publication date: May 23, 2019Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: Guochuan Emil Tsai
-
Patent number: 10160790Abstract: The disclosure features isolated polypeptides of Hyr1. The disclosure further features vaccines and antibodies useful in treating or preventing candidiasis or Acinetobacter infections or both. Further disclosed are isolated polypeptides consisting of between 14 and 20 amino acids for vaccine preparation. The specific amino acid sequences of isolated polypeptides of Hyr1 are also disclosed.Type: GrantFiled: September 14, 2012Date of Patent: December 25, 2018Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Ashraf S. Ibrahim, Michael R. Yeaman, John E. Edwards, Jr., Guanpingsheng Luo, Yue Fu
-
Patent number: 10149845Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: GrantFiled: January 19, 2017Date of Patent: December 11, 2018Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: Guochuan Emil Tsai
-
Patent number: 10130691Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.Type: GrantFiled: March 14, 2014Date of Patent: November 20, 2018Assignees: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, NovaDigm Therapeutics, Inc.Inventors: Ashraf S. Ibrahim, Michael R. Yeaman, Scott G. Filler, John E. Edwards, Jr., John P. Hennessey, Jr.
-
Patent number: 10058561Abstract: Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.Type: GrantFiled: August 27, 2014Date of Patent: August 28, 2018Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOInventors: Michael S. Kolodney, Adam M. Rotunda
-
Patent number: 10039730Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: GrantFiled: January 19, 2017Date of Patent: August 7, 2018Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: Guochuan Emil Tsai
-
Publication number: 20180215811Abstract: Presented herein, in certain embodiments, are compositions comprising antibody binding agents that specifically bind to A. baumannii and inhibit and/or block A. baumannii infection, and uses thereof.Type: ApplicationFiled: July 13, 2016Publication date: August 2, 2018Applicant: Los Angeles BioMedical Research Institute at Harbor-UCLA Medical CenterInventors: Brad SPELLBERG, Kevin BRUHN, Travis NIELSEN
-
Patent number: 9937227Abstract: Described herein are methods of enhancing chemotherapeutic treatment of a hyperproliferative disorder by, in part, administering a composition comprising one or more humanin polypeptides to a subject receiving chemotherapy.Type: GrantFiled: March 11, 2015Date of Patent: April 10, 2018Assignee: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTERInventors: Ronald S. Swerdloff, YanHe Lue, Christina Wang
-
Patent number: 9877671Abstract: Apparatus configured to detect congenital heart disease (CHD) in newborns may comprise a body with a cavity configured to receive a hand or foot of a newborn. Sensor pairs of the apparatus may be configured scan such that the best signals can be selected, which can accommodate for movements of the newborn and/or facilitate impartialness as to which body part is inserted in the apparatus. Positions of the sensor pairs may be adjusted to ensure contact with the newborn's skin. A disposable cover may protect the newborn's skin from contacting the apparatus. The apparatus may include a pressure device so that CHD threshold values can be adjusted for different altitudes. The apparatus may integrate with electronic medical record (EMR) systems.Type: GrantFiled: October 16, 2014Date of Patent: January 30, 2018Assignee: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR—UCLA MEDICAL CENTERInventor: Ruey-Kang Chang
-
Publication number: 20170343568Abstract: Described herein are methods for determining the overall survival of maintenance hemodialysis patients. The methods include measuring low density lipoprotein (LDL) particle size and subfraction concentrations as prognostic tools for early mortality risk detection. For example, the presence of increased very small LDL concentration or decreased LDL particle size in blood-serum serves as a useful means for prognostic risk assessment and monitoring.Type: ApplicationFiled: April 7, 2017Publication date: November 30, 2017Applicants: Quest Diagnostics Investments Incorporated, Los Angeles Biomedical Research InstituteInventors: Kamyar Kalantar-Zadeh, Michael P. Caulfield, Wael A. Salameh
-
Patent number: 9815869Abstract: The present invention relates to synthetic lung surfactant compositions that include a novel surface active peptide and a phospholipid, including phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, naturally occurring phospholipids, or a combination thereof. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue and to deliver therapeutic agents are also disclosed.Type: GrantFiled: February 11, 2013Date of Patent: November 14, 2017Assignees: University of Rochester, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Robert H. Notter, Alan J. Waring, Frans J. Walther, Larry M. Gordon, Zhengdong Wang
-
Patent number: 9763606Abstract: A method including placing a portion of a foot of a newborn in a device, the device including a light emitter and a corresponding receiver coupled on opposite sides of the device, the device further including a processor for processing data from the light emitter and receiver; and determining a presence of congenital heart disease. An apparatus including a body including a chamber of a size to accommodate a portion of a newborn's foot; at least one light emitter and a corresponding detector coupled on opposite sides of the body, the emitter configured to emit light of a prescribed wavelength into the chamber; and a processor coupled to the body and configured to receive a signal from the at least one detector.Type: GrantFiled: August 23, 2011Date of Patent: September 19, 2017Assignee: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTERInventors: Ruey-Kang Chang, Yann Ping Pan
-
Patent number: 9757043Abstract: A method and system for detection of pulsus paradoxus are provided. In one embodiment, the method includes determining a power spectrum density for a plethysmographic waveform and identifying pulsus paradoxus based on the power spectrum density. The power spectrum density may include a first wave peak indicative of a respiratory rate and a second wave peak indicative of a heart rate. Pulsus paradoxus can be identified by comparing a height of the first wave peak and a height of the second wave peak.Type: GrantFiled: June 17, 2013Date of Patent: September 12, 2017Assignee: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTERInventors: Gregory R. Mason, John M. Criley, Stuart R. Criley
-
Patent number: 9743882Abstract: An apparatus may be configured for documenting a code blue scenario when adhered to the chest of a subject undergoing resuscitation by sensing and transmitting information associated with the code blue scenario. Such information may include one or more of vital signs of the subject during resuscitation, information associated with chest movements of the subject during resuscitation, and audio information from an environment of the subject during resuscitation. A computing platform that is separate and distinct from the apparatus may provide code blue documentation conveying information related to the vital signs of the subject and derived from the audio information from the environment of the subject during resuscitation.Type: GrantFiled: April 4, 2014Date of Patent: August 29, 2017Assignee: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTERInventor: Ruey-Kang Chang
-
Publication number: 20170189358Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: ApplicationFiled: January 19, 2017Publication date: July 6, 2017Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: Guochuan Emil Tsai
-
Publication number: 20170181989Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: ApplicationFiled: January 19, 2017Publication date: June 29, 2017Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: Guochuan Emil Tsai
-
Patent number: 9675604Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: GrantFiled: November 24, 2014Date of Patent: June 13, 2017Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: Guochuan Emil Tsai